« Back
Home /
Dihydrokavain

Dihydrokavain

Item no.	HY-N0920-1mg
Manufacturer	MedChem Express
CASRN	587-63-3
Amount	1 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Feltenstein MW, et al. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother Res. 2003 Mar;17(3):210-6.\|[2]Rowe A, et al. Kavalactone pharmacophores for major cellular drug targets. Mini Rev Med Chem. 2011 Jan;11(1):79-83.\|[3]Xia Q, et al. Phototoxicity of kava - formation of reactive oxygen species leading to lipid peroxidation and DNA damage. Am J Chin Med. 2012;40(6):1271-88.\|[4]Bian T, et al. Kava as a Clinical Nutrient: Promises and Challenges. Nutrients. 2020 Oct 5;12(10):3044.\|[5]Anke J, et al. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol. 2004 Aug;93(2-3):153-60.\|[6]Jamieson DD, et al. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol. 1990 Jul;17(7):495-507.
Smiles	O=C1C=C(OC)C[C@H](CCC2=CC=CC=C2)O1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	7,8-Dihydrokawain,7,8-Dihydrokavain,Marindinin
Similar products	587-63-3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	COX; Cytochrome P450
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	232.279
Product Description	Dihydrokavain (7, 8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, CYP2C9 (IC50 = 130.95 μM), CYP2C19 (IC50 = 10.05 μM) and CYP3A4 (IC50 = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects[1][2][3][4][5].
Manufacturer - Research Area	Inflammation/Immunology; Neurological Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation; Metabolic Enzyme/Protease
Isoform	COX-1; COX-2; CYP2C19; CYP2C9; CYP3A4
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N0920-1mg-safety-datasheet.pdf